Login to Your Account



Outcome of hearing on CRISPR patents tough to predict

By Mark McCarty
Regulatory Editor

Thursday, December 8, 2016

The hearing at the U.S. Patent and Trademark Office regarding two patents for CRISPR is a pivotal moment for the IP associated with the technology, but Bob Underwood, a partner at the Chicago office of McDermott Will & Emery, said that prognostication on the outcome is a dicey exercise.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription